Kestra Medical Technologies, Ltd. Announces Closing of Upsized Initial Public Offering
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has successfully completed its upsized initial public offering (IPO). The company offered 11,882,352 common shares at $17.00 per share, generating total gross proceeds of approximately $202 million before deducting underwriting discounts and other expenses.
Trading of Kestra's common shares commenced on the Nasdaq Global Select Market on March 6, 2025, under the ticker symbol 'KMTS'. The IPO was led by BofA Securities, Goldman Sachs & Co. , and Piper Sandler as lead bookrunners, with Wells Fargo Securities and Stifel acting as bookrunners and Wolfe | Nomura Alliance as co-manager.
Kestra Medical Technologies (Nasdaq: KMTS), un'azienda di dispositivi medici indossabili e di assistenza sanitaria digitale, ha completato con successo la sua offerta pubblica iniziale (IPO) ampliata. L'azienda ha offerto 11.882.352 azioni ordinarie a 17,00 dollari per azione, generando proventi lordi totali di circa 202 milioni di dollari prima di dedurre gli sconti per l'underwriting e altre spese.
Le contrattazioni delle azioni ordinarie di Kestra sono iniziate sul Nasdaq Global Select Market il 6 marzo 2025, con il simbolo ticker 'KMTS'. L'IPO è stata guidata da BofA Securities, Goldman Sachs & Co., e Piper Sandler come bookrunner principali, con Wells Fargo Securities e Stifel che hanno agito come bookrunner e Wolfe | Nomura Alliance come co-manager.
Kestra Medical Technologies (Nasdaq: KMTS), una empresa de dispositivos médicos portátiles y atención médica digital, ha completado con éxito su oferta pública inicial (IPO) ampliada. La empresa ofreció 11.882.352 acciones ordinarias a 17,00 dólares por acción, generando ingresos brutos totales de aproximadamente 202 millones de dólares antes de deducir descuentos de suscripción y otros gastos.
La negociación de las acciones ordinarias de Kestra comenzó en el Nasdaq Global Select Market el 6 de marzo de 2025, bajo el símbolo de ticker 'KMTS'. La IPO fue liderada por BofA Securities, Goldman Sachs & Co., y Piper Sandler como bookrunners principales, con Wells Fargo Securities y Stifel actuando como bookrunners y Wolfe | Nomura Alliance como co-manager.
Kestra Medical Technologies (Nasdaq: KMTS), 착용 가능한 의료 기기 및 디지털 헬스케어 회사가 성공적으로 확대된 기업 공개(IPO)를 완료했습니다. 이 회사는 11,882,352주의 보통주를 주당 17.00달러에 제공하여, 언더라이팅 할인 및 기타 비용을 공제하기 전 약 2억 2천만 달러의 총 매출을 발생시켰습니다.
Kestra의 보통주 거래는 2025년 3월 6일에 Nasdaq Global Select Market에서 'KMTS'라는 티커 기호로 시작되었습니다. IPO는 BofA Securities, Goldman Sachs & Co., 및 Piper Sandler가 주요 북러너로 이끌었으며, Wells Fargo Securities와 Stifel이 북러너로, Wolfe | Nomura Alliance가 공동 매니저로 활동했습니다.
Kestra Medical Technologies (Nasdaq: KMTS), une entreprise de dispositifs médicaux portables et de santé numérique, a réussi à finaliser son introduction en bourse (IPO) élargie. L'entreprise a proposé 11.882.352 actions ordinaires à 17,00 dollars par action, générant des revenus bruts totaux d'environ 202 millions de dollars avant déduction des remises de souscription et d'autres frais.
La négociation des actions ordinaires de Kestra a commencé sur le Nasdaq Global Select Market le 6 mars 2025, sous le symbole boursier 'KMTS'. L'IPO a été dirigée par BofA Securities, Goldman Sachs & Co., et Piper Sandler en tant que principaux responsables de livre, avec Wells Fargo Securities et Stifel agissant en tant que responsables de livre et Wolfe | Nomura Alliance en tant que co-manager.
Kestra Medical Technologies (Nasdaq: KMTS), ein Unternehmen für tragbare medizinische Geräte und digitale Gesundheitsversorgung, hat erfolgreich sein erweitertes öffentliches Angebot (IPO) abgeschlossen. Das Unternehmen bot 11.882.352 Stammaktien zu einem Preis von 17,00 US-Dollar pro Aktie an und erzielte Gesamterlöse von etwa 202 Millionen US-Dollar, bevor Unterzeichnungskosten und andere Ausgaben abgezogen wurden.
Der Handel mit den Stammaktien von Kestra begann am Nasdaq Global Select Market am 6. März 2025 unter dem Tickersymbol 'KMTS'. Das IPO wurde von BofA Securities, Goldman Sachs & Co. und Piper Sandler als Hauptbuchführer geleitet, wobei Wells Fargo Securities und Stifel als Buchführer tätig waren und Wolfe | Nomura Alliance als Co-Manager fungierte.
- Successful completion of upsized IPO raising $202 million in gross proceeds
- Listing on prestigious Nasdaq Global Select Market
- Strong underwriter support from major investment banks
- Potential shareholder dilution from 11.88 million new shares
- IPO-related expenses will reduce the net proceeds available to the company
KIRKLAND, Wash., March 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, announced today the closing of its upsized initial public offering of 11,882,352 common shares at a public offering price of
BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler acted as lead bookrunners for the offering. Wells Fargo Securities and Stifel acted as bookrunners and Wolfe | Nomura Alliance acted as co-manager for the offering.
A registration statement relating to the common shares sold in this offering was filed with the Securities and Exchange Commission and became effective on March 5, 2025. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile at 212-902-9316, by email at Prospectus-ny@ny.email.gs.com, or by calling 1-866-471-2526; or Piper Sandler, by email at prospectus@psc.com, or by calling (800) 747-3924.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.
Disclaimer
“Wolfe | Nomura Alliance” is the marketing name used by Wolfe Research Securities and Nomura Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura Securities International, Inc. and WR Securities, LLC are serving as underwriters in the offering described herein. In addition, WR Securities, LLC and certain of its affiliates may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with this offering.
INVESTOR CONTACT
Marissa Bych or Webb Campbell
Gilmartin Group LLC
investor.relations@kestramedical.com
MEDIA CONTACT
Rhiannon Pickus
Kestra Medical Technologies, Ltd.
Rhiannon.Pickus@kestramedical.com
FAQ
How much did Kestra Medical Technologies (KMTS) raise in its IPO?
When did Kestra Medical Technologies (KMTS) begin trading on Nasdaq?
What was the IPO price for Kestra Medical Technologies (KMTS) shares?
Who were the lead underwriters for the Kestra Medical Technologies (KMTS) IPO?
